[1] Barroeta A B, Simonetti S, Vitale S, et al. GM - CSF inhibits c -kit and scf expression by bone marrow-derived dendritic cells. Front Immunol, 2017, 8(1): 146-147. [2] Parikh P, Ryan J D, Tsochatzis E A, et al. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection . Ann Transl Med, 2017, 5(3): 40 -53. [3] Xu Y, Tang X P, Zhang Y H, et al. Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample. Hepatology, 2015, 62(6): 1731–1741. [4] 程渝, 郭锐, 刘明国, 等. MRI与血清学定量指标检测对肝纤维化的诊断价值. 中华实用诊断与治疗杂志, 2018, 32(6):589-593. [5] 闫蓉, 高保华, 田秋梅, 等. RPR FIB-4 APRI及AAR对107例慢性乙型肝炎肝纤维化的诊断准确性比较. 中国实用内科杂志, 2019, 39(3):249-253. [6] 刘红, 吴疆. 国内外慢性乙型肝炎防治指南比较:抗病毒治疗诊断标准和治疗方案. 中国肝脏病杂志(电子版), 2018, 10(1):10-17. [7] Luo H, Zhang X X, Cao L H, et al. Serum hepatitis b virus rna is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis b patients. World J Gastroenterol, 2019, 25(6): 719–728. [8] Joshua D R, Ryan E, Robert H M, et al. Hepacivirus a infection in horses defines distinct envelope hypervariable regions and elucidates potential roles of viral strain and adaptive immune status in determining envelope diversity and infection outcome. J Virol, 2018 , 92(18): 14-18. [9] Motta M, Sejal M, Márcio T N, et al. A novel hepacivirus in wild rodents from south america. Viruses, 2019 ,11(3): 296-297. [10] 李军, 陈攀, 陈孝, 等. 以DJ-1蛋白为靶点治疗肝纤维化的研究进展. 中国药理学通报, 2018, 34(3):309-312. [11] Yan J, Kim E M, Choi M H, et al. Significance of serology by multi-antigen elisa for tissue helminthiases in Korea. J Korean Med Sci, 2017,32(7): 1118–1123. [12] Liao R, Fu Y P, Wang T, et al. Metavir and fib-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. Oncotarget, 2017 , 8(1): 1774–1787. [13] Sarin S K, Kumar M, Lau G K, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016 ,10(1): 1–98. [14] Tong M J, Pan C Q, Han S H, et al. An expert consensus for the management of chronic hepatitis b in Asian Americans. Aliment Pharmacol Ther,2018 ,47(8): 1181–1200. [15] Elia M C, Robert T S, Julia P A, et al. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis b patients. World J Gastroenterol, 2018, 24(17): 1825–1838. [16] 金彩婷,郭利伟,梁伟峰. 慢性乙型病毒性肝炎肝纤维化无创性血清诊断指标研究进展. 中华实验和临床感染病杂志(电子版), 2018, 12(1):11-14. [17] Zhang G L, Zhao Q Y, Lin C S, et al. Transient elastography and ultrasonography: optimal evaluation of liver fibrosis and cirrhosis in patients with chronic hepatitis B concurrent with nonalcoholic fatty liver disease. Biomed Res Int, 2019, 20(1): 3951-3957. [18] Yan L T, Wang L L, Yao J, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis b virus infection. Medicine (Baltimore), 2020, 99(8): 19248-19249. [19] Xu S H, Li Q , Hu Y P, et al. Development of a model based on biochemical, real-time tissue elastography and ultrasound data for the staging of liver fibrosis and cirrhosis in patients with chronic hepatitis B. Mol Med Rep, 2016, 14(4): 3609-3619. [20] Mak L Y, Danny K H, Cheung K S, et al. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol, 2018, 9(6): 163-164. [21] Sadhna D, Stephen C W, Swan N T, et al. Liver pathology of hepatitis C, beyond grading and staging of the disease. World J Gastroenterol, 2016, 22(4): 1357–1366. [22] Maria P S, Barbara K M, Małgorzata A, et al. Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C. BMC Infect Dis, 2017, 17(1): 355-361. [23] Wu N, Meng F y, Zhou T H, et al. The secretin/secretin receptor axis modulates ductular reaction and liver fibrosis through changes in transforming growth factor-β1–mediated biliary senescence. Am J Pathol, 2018, 188(10): 2264–2280. [24] Liu N, Feng J, Lu X Y, et al. Isorhamnetin inhibits liver fibrosis by reducing autophagy and inhibiting extracellular matrix formation via the tgf-β1/smad3 and tgf-β1/p38 mapk pathways. Mediators Inflamm, 2019, 20(1): 617-619. [25] Min H J, Ka Y H, Ji H P, et al. New mechanism of hepatic fibrogenesis: hepatitis c virus infection induces transforminggrowth factor β1 production through glucose-regulated protein 94. J Virol, 2016, 90(6): 3044–3055. |